Matthew Call - 11 Mar 2022 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Operating Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol
ITOS
Transactions as of
11 Mar 2022
Net transactions value
$0
Form type
4
Filing time
14 Mar 2022, 19:58:54 UTC
Previous filing
05 Aug 2021
Next filing
10 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Option (right to buy) Award $0 +85,000 $0.000000 85,000 11 Mar 2022 Common Stock 85,000 $36.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option shall vest over 4 years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer.